DAX Climbs To New Record High

German stocks are trading higher, with the DAX reaching a record high of 24,400.06, driven by better-than-expected factory orders data and anticipation of an ECB rate cut. Bayer is a leading gainer, up 5% following an upgrade to "buy" by Goldman Sachs and FDA approval for expanded use of its prostate cancer drug Nubeqa; however, a slight contraction in the construction sector, as indicated by the HCOB Germany Construction PMI, tempers overall enthusiasm.

Analysis

The German stock market exhibited strong performance, with the benchmark DAX reaching a new record high of 24,400.06 before trading at 24,363.44, an increase of 0.43% or 100.81 points, marking its third consecutive session of gains. This upward momentum is primarily attributed to encouraging factory orders data and widespread expectations of an imminent interest rate cut by the European Central Bank. German factory orders surpassed forecasts, rising 0.6% month-on-month in April, contrasting with an anticipated 1% decline, and demonstrated a robust 4.8% year-on-year expansion, accelerating from March's 3.7% revised growth. Excluding large-scale orders, new orders still saw a 0.3% month-on-month increase. Key corporate developments further bolstered sentiment, notably Bayer's 5% share price surge following a rating upgrade from 'neutral' to 'buy' by Goldman Sachs and U.S. FDA approval for the expanded use of its prostate cancer drug, Nubeqa. Other significant advancers included Heidelberg Materials (up nearly 3.5%), Daimler Truck Holding, Rheinmetall, Fresenius Medical Care, Brenntag, and Siemens Healthineers, which gained between 1% and 1.3%. However, this positive outlook is partially counterbalanced by weakness in the construction sector, as the HCOB Germany Construction PMI slipped to 44.4 in May, signaling a slightly faster contraction. Reflecting some underlying divergence, Airbus shares declined by 2%, while E.ON, Porsche, MTU Aero Engines, RWE, BMW, and Volkswagen also registered modest losses ranging from 0.2% to 0.8%.

Key Decisions for Investors

• Investors should closely monitor the European Central Bank's upcoming interest rate decision and accompanying forward guidance, as this is a key catalyst for the current market strength and will influence its sustainability.
• Bayer's significant positive developments, including a Goldman Sachs upgrade and FDA approval, warrant attention; however, after a 5% rally, a careful assessment of the entry point and risk-reward profile is prudent.
• The divergence between robust factory orders and a contracting construction PMI suggests a selective investment strategy within German equities, potentially favoring industrial companies with strong order backlogs over those heavily exposed to the domestic construction sector.